What happens after Ozempic shocked researchers
Why it matters: This offers a more optimistic future for long-term weight management post-GLP-1 drugs.
- Cleveland Clinic's real-world study, involving nearly 8,000 patients, found that stopping GLP-1 drugs does not typically lead to major weight regain, a significant departure from earlier clinical trial findings.
- Dr. Hamlet Gasoyan, lead researcher, highlights that patients in real-world settings often restart or transition to other obesity treatments, which helps explain the reduced weight regain compared to randomized trials.
- Patients treated for obesity in the study lost an average of 8.4% of their body weight before discontinuing the medication, with many maintaining stable weight over a year through alternative treatments and lifestyle support.
- Earlier randomized clinical trials had indicated that patients who stopped semaglutide or tirzepatide regained over half their lost weight within a year, a stark contrast to the new real-world evidence.
Contrary to fears of rapid weight regain, a new Cleveland Clinic study of nearly 8,000 patients reveals that many individuals discontinuing GLP-1 weight-loss drugs like Ozempic or Mounjaro successfully maintain or even continue losing weight. This real-world data challenges earlier clinical trials by showing that patients often restart treatment, switch medications, or adopt lifestyle changes, offering a more hopeful outlook for long-term weight management.
